U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07213440) titled 'Identification of Early Markers for ALS' on Jan. 08.
Brief Summary: Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.
In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.
Study Start Date: Sept. 30, 2024
...